Correction of anemia using an iron supplement with a hepcidin-independent absorption mechanism in patients with chronic heart failure with preserved left ventricular ejection fraction

Aim. To characterize anaemia in chronic heart failure (CHF) with preserved left ventricular ejection fraction (CHFpEF) and evaluate the effectiveness of an iron supplement with a hepcidin- independent absorption mechanism.   Material and methods. An uncontrolled study included 30 patients with CHFpE...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Gurkina, N. I. Stuklov, V. A. Kokorin, R. R. Gimadiev, N. V. Varekha
Format: Article
Language:English
Published: Столичная издательская компания 2025-04-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/3121
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. To characterize anaemia in chronic heart failure (CHF) with preserved left ventricular ejection fraction (CHFpEF) and evaluate the effectiveness of an iron supplement with a hepcidin- independent absorption mechanism.   Material and methods. An uncontrolled study included 30 patients with CHFpEF NYHA class I-III and anaemia. Patients received "standard therapy" for CHF in combination with sucrosomial iron (60 mg/day orally) for three months. Treatment response was assessed via clinical blood test, iron metabolism parameters, inflammatory markers, and functional tests at baseline and three months post-treatment.   Results. Anaemia in CHFpEF corresponds to anaemia of chronic disease with elevated hepcidin content, 219 (149-553) ng/mL occurs with impaired absorption and metabolism of iron and the development of iron deficiency. Hemoglobin levelincreased from 115 (98-117) g/L to 120 (103-133) g/L, p = 0.01, red blood cell count increased from 3.6 (3.5-4.1) × 1012/L to 4 (3.7-5.3) × 1012/L, p = 0.05, and serum ferritin increased from 106 (40-181) μg/L to 117 (83-166) μg/L, p = 0.04. N-terminal natriuretic propeptide (NT-proBNP) level decreased from 374 (330-443) ng/mL to 236 (128-349) ng/mL, p = 0.004. After treatment, exercise tolerance exercise tolerance improved: 6-minute walk test distance increased from 343.1 ± 100 m to 397±73 m (p = 0.01). Quality of life (QoL) level increased and was determined by the clinical status assessment scale (CAS), p = 0.01 and by the Minnesota Health Failure Questionnaire (MHFLQ), p = 0.002.   Conclusion. Adding oral hepcidin- independent iron to standard HFpEF therapy in patients with CHFpEF and anaemia significantly increased hemoglobin and serum ferritin levels, exercise tolerance, and QoL scores while reducing NT-proBNP levels and NYHA functional class after three months.
ISSN:1819-6446
2225-3653